Neonc Technologies (NASDAQ:NTHI) CEO Amir Heshmatpour Acquires 9,000 Shares of Stock

Neonc Technologies Holdings, Inc. (NASDAQ:NTHI) CEO Amir Heshmatpour acquired 9,000 shares of Neonc Technologies stock in a transaction that occurred on Tuesday, August 18th. The stock was purchased at an average cost of $5.54 per share, with a total value of $49,860.00. Following the completion of the purchase, the chief executive officer owned 3,096,000 shares in the company, valued at $17,151,840. The trade was a 0.29% increase in their position. The purchase was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Neonc Technologies Stock Up 16.5%

NASDAQ NTHI traded up $0.81 during trading hours on Tuesday, hitting $5.72. 253,076 shares of the company’s stock traded hands, compared to its average volume of 93,199. Neonc Technologies Holdings, Inc. has a 52-week low of $3.01 and a 52-week high of $12.99. The firm’s 50-day moving average is $4.11 and its 200-day moving average is $6.05.

Neonc Technologies (NASDAQ:NTHI) last released its earnings results on Friday, August 14th. The company reported ($0.58) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.12) by ($0.46).

Institutional Inflows and Outflows

Large investors have recently bought and sold shares of the stock. Bank of America Corp DE purchased a new position in Neonc Technologies during the second quarter worth about $1,017,000. BlackRock Inc. acquired a new position in shares of Neonc Technologies in the 2nd quarter worth approximately $815,000. Global Retirement Partners LLC acquired a new position in shares of Neonc Technologies in the 2nd quarter worth approximately $126,000. Westmount Partners LLC boosted its position in shares of Neonc Technologies by 355.2% during the 2nd quarter. Westmount Partners LLC now owns 197,178 shares of the company’s stock worth $893,000 after purchasing an additional 153,858 shares during the period. Finally, 683 Capital Management LLC purchased a new position in shares of Neonc Technologies during the 4th quarter worth approximately $442,000.

More Neonc Technologies News

Here are the key news stories impacting Neonc Technologies this week:

• Positive Sentiment: NeOnc reported that a Phase 2a study of NEO100 in patients with recurrent IDH1-mutant high-grade glioma met its endpoint and extended survival. The results strengthen the company’s clinical narrative and could improve confidence in its CNS drug-development platform, although the program remains early-stage and still faces additional clinical and regulatory hurdles. Neonc NEO100 Hits Phase II Endpoint, Extends Survival in Recurrent Glioma
• Positive Sentiment: CEO Amir Heshmatpour bought 12,000 shares on August 14 at approximately $3.79 each and another 3,000 shares on August 17 at approximately $4.37 each, investing roughly $58,600 in total. The purchases increased his already substantial ownership to about 3.087 million shares and may be viewed as a signal of management confidence. NeOnc Technologies- Talk Is Cheap, Insider Buying Isn’t
• Neutral Sentiment: Analyst coverage remains broadly constructive, with several Buy ratings and price targets well above recent trading levels, but the overall consensus is Hold because at least one analyst has issued a Sell rating. Reported purchases by several institutional investors also provide some support, though they do not eliminate the company’s clinical and financing risks.
• Negative Sentiment: Stockholders approved expanding the company’s equity plan by 1 million shares. The additional authorization could help fund operations and development, but it also creates potential dilution for existing shareholders. NeOnc Stockholders Elect Directors, Approve 1M-Share Equity Plan Expansion
• Negative Sentiment: NeOnc reported a quarterly loss of $0.58 per share, substantially worse than the $0.12 loss analysts expected. The result highlights the company’s lack of near-term profitability and ongoing need for capital while it advances NEO100.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on NTHI shares. Alliance Global Partners initiated coverage on Neonc Technologies in a research note on Tuesday, May 19th. They issued a “buy” rating and a $13.00 target price for the company. Weiss Ratings lowered shares of Neonc Technologies from a “sell (d-)” rating to a “sell (e+)” rating in a report on Wednesday, June 24th. Wall Street Zen cut shares of Neonc Technologies from a “hold” rating to a “sell” rating in a research report on Saturday. Maxim Group began coverage on shares of Neonc Technologies in a research note on Monday, May 18th. They set a “buy” rating and a $20.00 target price on the stock. Finally, BTIG Research reiterated a “buy” rating and issued a $15.00 target price on shares of Neonc Technologies in a report on Tuesday, May 26th. Three equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has a consensus rating of “Hold” and an average target price of $16.00.

About Neonc Technologies

Neonc Technologies Holdings, Inc develops novel molecular technology that provides enhanced targeted delivery of technologies for treating central nervous system diseases. Its lead products in development include NEO100, which is in Phase 2a clinical trials for treating glioblastoma; and NEO212, a covalently conjugated molecule combining the chemotherapeutic drug temozolomide with perillyl alcohol that is completed preclinical testing. The company was incorporated in 2023 and is based in Los Angeles, California.